- ISIN
- US69012T2069
- CUSIP
- 69012T206
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 13, 2016
Highlights
- Market Cap
- $66.58M
- Enterprise Value
- -$7.47T
- EPS (TTM)
- -$104.94K
- Total Revenue (TTM)
- $127.44B
- Gross Profit (TTM)
- -$21.89B
- EBITDA (TTM)
- -$14.03T
- Year Range
- $0.16 - $3.39
- Target Price
- $1.00
- ROA (TTM)
- -20.34%
- ROE (TTM)
- 15.36%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
OTLK Performance Chart
Outlook Therapeutics, Inc. (OTLK) is down 48.5% since the beginning of the year. At $1 per share, OTLK is trading 76.0% below its 52-week high of $3. Investors who bought $1,000 worth of OTLK shares 5 years ago would now be looking at an investment worth $16.
Loading charts...
Returns By Period
Outlook Therapeutics, Inc. (OTLK) has returned -48.51% so far this year and -54.03% over the past 12 months.
Outlook Therapeutics, Inc.
- 1D
- -3.49%
- 1M
- 210.30%
- YTD
- -48.51%
- 6M
- -55.54%
- 1Y
- -54.03%
- 3Y*
- -70.63%
- 5Y*
- -56.49%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
OTLK Monthly Returns History
Based on dividend-adjusted daily data since Jun 14, 2016, OTLK's average daily return is +0.05%, while the average monthly return is +1.37%. At this rate, an investment would double in approximately 4.2 years.
Historically, 44% of months were positive and 56% were negative. The best month was May 2026 with a return of +192.0%, while the worst month was Aug 2023 at -86.8%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, OTLK closed higher 44% of trading days. The best single day was Sep 8, 2017 with a return of +124.4%, while the worst single day was Aug 30, 2023 at -81.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -72.17% | -4.32% | -51.08% | 21.48% | 192.00% | 11.45% | -48.51% | ||||||
| 2025 | 8.99% | -27.18% | -18.67% | 28.69% | 17.20% | -13.04% | 22.50% | -56.57% | 24.53% | 18.87% | 42.06% | -11.73% | -16.40% |
| 2024 | -2.03% | 13.16% | 36.68% | -25.29% | -20.74% | 4.38% | 5.01% | -5.16% | -27.35% | 7.87% | -64.41% | -7.80% | -76.02% |
| 2023 | 6.48% | -5.22% | -0.00% | -3.67% | 42.86% | 16.00% | -0.57% | -86.82% | -3.07% | 171.49% | -20.00% | -17.92% | -63.52% |
| 2022 | 4.41% | 14.79% | 9.20% | -12.92% | -25.81% | -11.30% | 10.78% | -0.88% | 8.93% | -4.92% | -10.34% | 3.85% | -20.59% |
| 2021 | -28.07% | 132.06% | 3.69% | 5.78% | 12.61% | -7.09% | -9.24% | 22.12% | -21.38% | -4.61% | -27.05% | -9.93% | 4.62% |
Benchmark Metrics
Outlook Therapeutics, Inc. has an annualized alpha of -0.30%, beta of 0.80, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since June 15, 2016.
- This stock participated in 173.92% of S&P 500 Index downside but only -76.25% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -0.30%
- Beta
- 0.80
- R²
- 0.01
- Upside Capture
- -76.25%
- Downside Capture
- 173.92%
Return for Risk
Risk / Return Rank
OTLK ranks 31 for risk / return — below 31% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Outlook Therapeutics, Inc. (OTLK) and compare them to S&P 500 Index.
| OTLK | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.36 | 2.39 | -2.75 |
Sortino ratioReturn per unit of downside risk | 0.49 | 3.25 | -2.76 |
Omega ratioGain probability vs. loss probability | 1.08 | 1.43 | -0.36 |
Calmar ratioReturn relative to maximum drawdown | -0.58 | 3.11 | -3.69 |
Martin ratioReturn relative to average drawdown | -0.84 | 14.38 | -15.22 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Outlook Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Outlook Therapeutics, Inc. was 99.98%, occurring on Mar 24, 2026. The portfolio has not yet recovered.
The current Outlook Therapeutics, Inc. drawdown is 99.91%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.98%Mar 2026 | 9y 6mo | — | 9y 9moSep 2016 - now |
2016 bear market2016 | -29.29%Aug 2016 | 1mo 17d | 28d | 2mo 15dJun 2016 - Aug 2016 |
2016 pullback2016 | -3.06%Sep 2016 | 0s | 4d | 4dSep 2016 - Sep 2016 |
2016 pullback2016 | -1.71%Jun 2016 | 0s | 1d | 1dJun 2016 - Jun 2016 |
Drawdown Indicators
| OTLK | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.98% | -56.78% | -43.20% |
Max Drawdown (1Y)Largest decline over 1 year | -93.33% | -9.10% | -84.23% |
Max Drawdown (3Y)Largest decline over 3 years | -99.48% | -18.90% | -80.58% |
Max Drawdown (5Y)Largest decline over 5 years | -99.64% | -25.43% | -74.21% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.91% | 0.00% | -99.91% |
Average DrawdownAverage peak-to-trough decline | -88.69% | -10.72% | -77.97% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 64.48% | 1.97% | +62.51% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Outlook Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Outlook Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for OTLK relative to other companies in the Biotechnology industry. Currently, OTLK has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with OTLK
Add Outlook Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with OTLK